Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis.

Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS, Graham BS, McLellan JS, Ward AB.

Sci Rep. 2018 Dec 10;8(1):17823. doi: 10.1038/s41598-018-36918-8.

2.

A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry.

Rosen O, Chan LL, Abiona O, Gough P, Wang L, Shi W, Zhang Y, Wang N, Kong WP, McLellan JS, Graham BS, Corbett KS.

J Virol Methods. 2018 Nov 20. pii: S0166-0934(18)30318-5. doi: 10.1016/j.jviromet.2018.11.009. [Epub ahead of print]

PMID:
30468747
3.

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis.

Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS, Graham BS, McLellan JS, Ward AB.

Sci Rep. 2018 Oct 24;8(1):15701. doi: 10.1038/s41598-018-34171-7. Erratum in: Sci Rep. 2018 Dec 10;8(1):17823.

4.

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation.

Lancet Infect Dis. 2018 Oct;18(10):e295-e311. doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18. Review. Erratum in: Lancet Infect Dis. 2018 Jul 25;:.

PMID:
29914800
5.

Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Are Critical for Its Fusion Activity.

Hicks SN, Chaiwatpongsakorn S, Costello HM, McLellan JS, Ray W, Peeples ME.

J Virol. 2018 Jul 17;92(15). pii: e00621-18. doi: 10.1128/JVI.00621-18. Print 2018 Aug 1.

PMID:
29743373
6.

Global site-specific analysis of glycoprotein N-glycan processing.

Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SR, Delahunty CM, McLellan JS, Burton DR, Yates JR, Paulson JC.

Nat Protoc. 2018 Jun;13(6):1196-1212. doi: 10.1038/nprot.2018.024. Epub 2018 May 3.

PMID:
29725121
7.

Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape.

Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster VJ, Mascola JR, Graham BS.

J Virol. 2018 Mar 7. pii: JVI.02002-17. doi: 10.1128/JVI.02002-17. [Epub ahead of print]

8.

Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.

Jones HG, Ritschel T, Pascual G, Brakenhoff JPJ, Keogh E, Furmanova-Hollenstein P, Lanckacker E, Wadia JS, Gilman MSA, Williamson RA, Roymans D, van 't Wout AB, Langedijk JP, McLellan JS.

PLoS Pathog. 2018 Mar 6;14(3):e1006935. doi: 10.1371/journal.ppat.1006935. eCollection 2018 Mar.

9.

Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, Bai P, Sivasubramanian A, Connor RI, Wright PF, Graham BS, McLellan JS, Walker LM.

Immunity. 2018 Feb 20;48(2):339-349.e5. doi: 10.1016/j.immuni.2018.01.005. Epub 2018 Feb 3.

10.

Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses.

Olmedillas E, Cano O, Martínez I, Luque D, Terrón MC, McLellan JS, Melero JA, Más V.

EMBO Mol Med. 2018 Feb;10(2):175-187. doi: 10.15252/emmm.201708078.

11.

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.

Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS, McLellan JS, Graham BS.

Nat Commun. 2017 Nov 30;8(1):1877. doi: 10.1038/s41467-017-01858-w.

12.

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Nov 29;8:16165. doi: 10.1038/ncomms16165.

13.

Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein.

Battles MB, Más V, Olmedillas E, Cano O, Vázquez M, Rodríguez L, Melero JA, McLellan JS.

Nat Commun. 2017 Nov 16;8(1):1528. doi: 10.1038/s41467-017-01708-9.

14.

Clinical Potential of Prefusion RSV F-specific Antibodies.

Rossey I, McLellan JS, Saelens X, Schepens B.

Trends Microbiol. 2018 Mar;26(3):209-219. doi: 10.1016/j.tim.2017.09.009. Epub 2017 Oct 17. Review.

PMID:
29054341
15.

Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus.

Li Z, Wang D, Gu Y, Song S, He M, Shi J, Liu X, Wei S, Li J, Yu H, Zheng Q, Yan X, Baker TS, Zhang J, McLellan JS, Li S, Xia N.

MBio. 2017 Sep 26;8(5). pii: e00787-17. doi: 10.1128/mBio.00787-17.

16.

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS.

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357. doi: 10.1073/pnas.1707304114. Epub 2017 Aug 14.

17.

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.

Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein P, Rigaux P, Berg JVD, Kwanten L, Ginderen MV, Verheyen N, Vranckx L, Jaensch S, Arnoult E, Voorzaat R, Gallup JM, Larios-Mora A, Crabbe M, Huntjens D, Raboisson P, Langedijk JP, Ackermann MR, McLellan JS, Vendeville S, Koul A.

Nat Commun. 2017 Aug 1;8(1):167. doi: 10.1038/s41467-017-00170-x.

18.

Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.

Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Jul 12;91(15). pii: e00189-17. doi: 10.1128/JVI.00189-17. Print 2017 Aug 1.

19.

Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.

Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.

J Virol. 2017 Jul 12;91(15). pii: e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1.

20.

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA.

Sci Transl Med. 2017 May 3;9(388). pii: eaaj1928. doi: 10.1126/scitranslmed.aaj1928.

PMID:
28469033

Supplemental Content

Loading ...
Support Center